Health
Ultrapotent compound may help treat C. diff, reduce recurrence – Medical Xpress
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Preventio…
-
Noosa News17 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General23 hours agoNew Spirit of Tasmania ferry arrives in Hobart, but will not be operating for more than a year
-
Noosa News23 hours agoScientists move precious ReefHQ coral ahead of Great Barrier Reef Aquarium build
-
General24 hours agoWA government is ‘spinning’ the results of community survey into Burswood Park racetrack and community hub, locals say